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Effects of Naltrexone Treatment for Alcohol-Related
Disorders on Healthcare Costs in an Insured Population
Henry R. Kranzler, Leslie B. Montejano, Judith J. Stephenson, Shaohung Wang,
and David R. Gastfriend
Objective: To determine the impact of treatment with oral naltrexone on healthcare costs in
patients with alcohol-related disorders.
Methods: Using data from the MarketScan Commercial Claims and Encounters Database for
2000–2004, we identified a naltrexone group (with an alcohol-related diagnosis and at least one
pharmacy claim for oral naltrexone) and two control groups. Alcohol controls had an alcohol-
related diagnosis and were not prescribed an alcoholism treatment medication. Nonalcohol controls
had no alcohol-related diagnosis and no prescription for an alcoholism treatment medication.
The control groups were matched three to one to the naltrexone group on demographic and other
relevant measures. Healthcare expenditures were calculated for the 6-month periods before and
after the index naltrexone drug claim (or matched date for controls). Univariate and multivariate
analyses were used to compare the groups on key characteristics and on healthcare costs.
Results: Naltrexone patients (n = 1,138; 62% men; mean age 45 ± 11 years) had significantly
higher total healthcare expenditures in the pre-index period than either of the control groups. In
the postindex period, naltrexone patients had a significantly smaller increase than alcohol controls
in total alcohol-related expenditures. Total nonalcohol-related expenditures also increased signifi-
cantly less for the naltrexone group than for the alcohol control group. Multivariate analyses
showed that naltrexone treatment significantly reduced alcohol-related, nonalcohol-related, and
total healthcare costs relative to alcohol controls.
Conclusions: Although prior to treatment patients with alcohol-related disorders had higher
healthcare costs, treatment with oral naltrexone was associated with reductions both in alcohol-
related and nonalcohol-related healthcare costs.
Key Words: Naltrexone, Alcohol-Related Disorders, Healthcare Costs, Alcoholism,
Pharmacoeconomics.
A LCOHOL USE DISORDERS (AUDs, which includealcohol abuse and alcohol dependence) are highly pre-
valent in the United States, with nearly 8.5% of the popula-
tion meeting current (i.e., past-year) criteria for these
disorders (Grant et al., 2004). AUDs are of considerable pub-
lic health and economic significance, because of the high fre-
quency of associated medical, psychiatric, family, legal, and
work-related problems (Caetano and Cunradi, 1997). The
annual cost of AUDs in the United States was estimated to
be nearly $185 billion for 1998 (Harwood, 2000), which in
view of rising healthcare costs, is likely to be a substantial
underestimate of current costs.
Despite the adverse effects of AUDs, the vast majority of
individuals with these disorders never receive treatment
(Cohen et al., 2007; Mojtabai et al., 2002; Rabinowitz et al.,
1999; Regier et al., 1993; Wu et al., 2003). Recent efforts to
improve both the efficacy and the acceptability of alcohol
treatment have included the identification and testing of
medications to treat alcohol dependence. This effort has
resulted in the approval by the U.S. Food and Drug Admin-
istration of two oral medications (naltrexone and acam-
prosate), as well as a new, injectable, extended-release
naltrexone formulation (Garbutt et al., 2005). These medica-
tions are in addition to disulfiram, which was approved
during the mid-20th century.
A substantial literature shows that interventions to reduce
heavy drinking or prevent relapse in alcoholism result in
reduced healthcare costs, even when the cost of the treatment
is accounted for (e.g., Holder, 1998; Holder and Blose, 1992;
Parthasarathy et al., 2001; Pettinati et al., 1999). Pettinati and
colleagues (1999) examined the effects of different modalities
of alcohol treatment on this cost offset. Kranzler and collea-
gues (2008) used data from the 2000 to 2004 MarketScan
Commercial Claims and Encounters Database to identify
patients with alcohol-related claims who were prescribed oral
naltrexone. Of 1,138 patients, 162 (14.2%) were persistent in
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obtaining naltrexone, which was defined as having filled
prescriptions for ‡80% of the 6-month treatment period.
Nonpersistence with naltrexone was associated with a signifi-
cantly greater use of costly healthcare services. That study did
not, however, compare healthcare utilization by naltrexone-
treated patients with that of other patients. Hence, this study
compared healthcare costs for patients with an alcohol-related
disorder who received naltrexone treatment with those of
individuals with an alcohol-related disorder who were not
prescribed pharmacotherapy and with a group of nonalco-
holic individuals.
METHODS
The study used the MarketScan Commercial Claims and
Encounters (Commercial) Database for healthcare services incurred
during the 5-year period January 1, 2000 through December 31,
2004. The healthcare business of the information company Thom-
son Reuters (New York, NY) constructs the MarketScan data-
bases from the paid medical and prescription drug claims of
individuals insured through its large self-insured employer and
health plan clients located throughout the United States. In con-
structing the databases, information on healthcare claims from
almost 100 payers, including self-insured employers, commercial
insurance companies, Blue Cross and Blue Shield plans, and third-
party administrators, is standardized and de-identified so that the
resulting databases can be used to study real-world treatment
patterns.
The resulting commercial database included the healthcare claims
of 12 million insured individuals per year, on average, from 2000
through 2004. The claims come from all types of healthcare providers
that submit information for payment to health plans and other pay-
ers, including hospitals, residential treatment facilities, physician offi-
ces, clinics, and retail and mail-order pharmacies. Each record in the
database represents a unique healthcare service for which payment
was requested. Individual database records (i.e., claims) were com-
piled at the patient level to study the healthcare utilization patterns
of covered individuals. In addition to claims, basic demographic and
health plan enrollment information is included in the database.
Approximately 40% of health plans and other payers included in the
database do not cover or they carve out substance abuse treatment.
To avoid including patients with incomplete data, we limited the
study sample to patients who had substance abuse coverage through
their health plans.
Sample Selection Criteria
The naltrexone group had one or more claims for oral naltrex-
one between July 1, 2000 and June 30, 2004, the earliest of which
occurring during this period was set as the study index date.
Patients who were not continuously enrolled in a health plan for
6 months before and 6 months after the index date were excluded
because their claims histories during the study period would be
incomplete. Because the aim of the study was to compare health-
care utilization and expenditures before and after the initiation of
oral naltrexone therapy, patients with claims for naltrexone (as well
as disulfiram or acamprosate, which could confound the analyses)
in the 3 months pre-index were excluded from the analysis.
Patients with earlier pre-index claims for these drugs were retained
in the sample because a 3-month gap in therapy was deemed to
reflect a new course of treatment. Because the data were from the
period preceding the availability of extended-release naltrexone for
clinical use, there were no claims for that medication. To focus the
analysis on patients who were receiving naltrexone to treat an alco-
hol use disorder, patients without one or more alcohol-related
diagnoses in the 6 months before or after the index date were
excluded.
Alcohol-related diagnoses were defined broadly using the criteria
of the International Classification of Diseases, Ninth Revision, Clini-
cal Modification (ICD-9-CM) and a list of diagnoses from Harwood
and colleagues (1998). The following alcohol-related conditions were
represented to ensure that all individuals with clinically significant
effects of alcohol were included: Alcoholic psychoses; alcohol depen-
dence syndrome; nondependent abuse of alcohol; alcoholic poly-
neuropathy; alcoholic cardiomyopathy; alcoholic gastritis; alcoholic
fatty liver; acute alcoholic hepatitis; alcoholic cirrhosis of the liver;
alcoholic liver damage, unspecified; fetal alcohol syndrome (in which
case the mother was identified as the patient); excessive blood level of
alcohol; toxic effects of ethyl alcohol; and accidental poisoning by
alcohol.
Two control groups were selected for the analysis: (i) Alcohol con-
trols were patients with one or more claims for an alcohol-related
diagnosis; no drug claims for naltrexone, disulfiram or acamprosate;
and 6 months of continuous enrollment prior to the index date and
following the index date. (ii) Nonalcohol controls were patients with
no claims for an alcohol-related diagnosis; no drug claims for nal-
trexone, disulfiram or acamprosate; and 6 months of continuous
enrollment prior to the index date and following the index date.
Because these
All patients in the database meeting the control sample criteria
were eligible to be matched to the naltrexone sample for analysis. To
ensure an even distribution of demographic characteristics that could
influence healthcare utilization in all cohorts, thereby reducing con-
founding, both the alcohol controls and the nonalcohol controls were
individually matched 3:1 to patients in the naltrexone group on the
basis of gender, age, geographic region, relationship to primary
insured, health plan type, and index quarter ⁄year. Matches were
assigned randomly from among all patients in the database who met
the control sample criteria. The match ratio was chosen to enhance
the capacity to detect potential cost differences because, although
costs are generally highly skewed, even a small cost difference
between groups could be meaningful. Because matching more than 3
controls to each case usually does not add power, a 3:1 match ratio
was used (Mandrekar andMandrekar, 2004).
Variables
Index Date. To determine the costs associated with naltrexone
treatment, we chose an index date, which was the date from which
we started to calculate healthcare costs and expenditures. For the nal-
trexone group, the index date was the date of the earliest naltrexone
claim, between July 1, 2000 and June 30, 2004. The inclusion criteria
required a 3-month ‘‘clean period’’ before the earliest naltrexone
claim; this prevented confounding by the effects of recent pharmaco-
therapy for an alcohol-related diagnosis. Hence, the index date
represented the initiation of naltrexone therapy, following at
least 3 months with no evidence of alcohol-related pharmacotherapy
(naltrexone, disulfiram, or acamprosate).
The index date for the control groups was randomly assigned such
that the distribution of index dates by year and quarter did not differ
significantly from that of the naltrexone cohort. The pre-index period
was defined as the 6 months immediately preceding the index date.
The postindex period started on the index date and continued for
6 months.
Demographic and Clinical Measures. The following standard
demographic variables were available on insurance claims and
included in the analysis: sex, age in years at index, geographic region
(northeast, north central, south, west), relationship of patient to pri-
mary insured (self ⁄ employee, spouse, child ⁄other), capitated insur-
ance (yes, no), and insurance plan type (basic, comprehensive, EPO,
HMO, noncapitated POS, PPO, capitated POS). These measures
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were selected because of their potential impact on healthcare
expenditures.
To assess co-occurring medical conditions present in the pre-index
and the postindex periods we used two claims-based comorbidity
indices, the Charlson Comorbidity Index (CCI) (D’Hoore et al.,
1996) and the Chronic Disease Score (CDS) (Von Korff et al., 1992).
The CCI, one of the most widely used measures of the combined bur-
den of disease or conditions (Valderas et al., 2009), is based on ICD-
9-CM diagnosis codes. The CDS is a risk-adjustment measure based
on age, gender, and history of dispensed drugs that predicts hospital-
ization and can be used as an indicator of baseline comorbidity for
control of confounding (Putnam et al., 2002). Although for both
measures, higher scores indicate a greater burden of comorbidity,
because they can yield slightly different results, both were used to
control for the impact that the treatment of comorbid conditions has
on total expenditures.
Alcohol-Related and Drug-Related Diagnoses. Patients were
identified as having an alcohol-related condition if they had at least
one medical claim with one of the alcohol-related ICD-9-CM diagno-
sis codes (Harwood et al., 1998). The diagnosis code could be present
on any diagnosis field (primary or secondary) and on any type of
claim [inpatient, emergency department (ED), outpatient]. Patients
were identified as having a drug-related condition if they had at least
one medical claim for one of the drug-related ICD-9-CM diagnosis
codes (Harwood et al., 1998). Separate binary (yes ⁄no) alcohol and
drug diagnosis variables were created for the 6-month pre-index per-
iod and the 6-month study period.
Medical Care Costs. We calculated total healthcare payments
using the gross payment field on inpatient, outpatient, and prescrip-
tion claims. The gross payment represents the total amount eligible
for payment for a service, including both the health plan and the
patient (e.g., copayment, deductible) portions. All costs were adjusted
to December 2004 dollars using the medical component of the
Consumer Price Index (CPI). Separate figures were tallied for
the 6-month pre-index period and the 6-month postindex period. In
addition to providing a sum of total expenditures, we reported expen-
ditures associated with specific subsets of claims. Subgroups exam-
ined included place or type of service (i.e., inpatient hospital, ED,
outpatient, and outpatient pharmacy). We also divided expenditures
into alcohol-related and nonalcohol-related, on the basis of the
primary diagnosis code listed on each claim. Alcohol-related expendi-
tures included inpatient, ED, and outpatient services claims where
the primary diagnosis was an alcohol-related code, and drug claims
for naltrexone. We considered only primary diagnoses in attributing
costs as alcohol-related because of the potential to over count ser-
vices if the secondary diagnosis referred to a mitigating factor rather
than the reason for treatment. All other claims were considered
nonalcohol related.
Medical Care Utilization. We examined medical care utilization
rates by place or type of service (i.e., inpatient hospitalizations, ED
visits, outpatient visits, and outpatient pharmacy prescriptions). For
each place or type of service, we created a binary (yes ⁄no) variable
denoting the presence of any service and a continuous variable to
record the number of relevant services. As with costs, utilization was
examined overall and for alcohol-related services as identified by
diagnoses on the claims.
In addition, we identified patients with certain types of alcohol-
related treatment, including individual psychotherapy, group psycho-
therapy, outpatient detoxification, and inpatient detoxification. This
information was obtained for both the 6-month pre-index period and
the 6-month postindex period. Procedure codes present on claims
were used to identify patients with these services. In addition,
MarketScan place of service codes were used to differentiate inpatient
and outpatient detoxification.
Descriptive Analyses
Descriptive information included the demographic and clinical
characteristics of the naltrexone group and both control groups, as
well as their utilization and expenditures in the pre-index period and
study period. Dependent variables also included utilization and cost
measures, as well as specific measures of alcohol-related medical com-
plications. Utilization included: (i) number of outpatient visits, (ii)
number of hospitalizations, (iii) number of days hospitalized, (iv)
number of ED visits, (v) number of prescriptions, and (vi) sum of days
supplied across all prescriptions. Cost measures were calculated as
paid claims after discounts. Cost measures included: (i) total medical
care expenditures, (ii) outpatient expenditures, (iii) inpatient expendi-
tures, (iv) ED expenditures, and (v) pharmaceutical expenditures.
Statistical testing was used to examine differences between the nal-
trexone and control samples. t-tests were used to analyze normally
distributed continuous variables, Wilcoxon rank-sum tests to analyze
non-normally distributed continuous variables, and chi-square tests
were used to analyze categorical variables. To account for within-
subject correlation, paired t-tests were used to test the difference
between the pre-index and postindex period expenditures.
Multivariate Analyses
Multivariate analyses were used to provide cost estimates that con-
trol for confounding factors. The final specification of the multivari-
ate models was driven, in part, by the results of the descriptive
analysis. Difference-in-difference (DID) regression analyses were
used to generate a more accurate estimate of the total expenditure
impact of naltrexone treatment.
Each individual had two observations: one in the period before the
index date and one in the period after the index date. The generalized
estimating equation (GEE) method was used to account for
correlation between repeated measures across individuals. Nonlinear
specification of the cost equation was estimated to account for the
non-normal distribution of the error term (Liang and Zeger, 1986).
The general specification of the DID regression was as follows:
Total $ = f (T, Alcohol Control, T*Alcohol Control, Nonalcohol
Control, T*Nonalcohol Control, X).
In this specification, Total $ refers to total healthcare expenditures
in the pre-index and postindex periods (measured separately for each
patient). The letter f refers to the assumption of a formal, empirical
(i.e., exponential) relationship between healthcare expenditures and
the factors in parentheses. ‘‘T’’ indicates whether the outcome is mea-
sured before or after treatment. ‘‘Alcohol Control’’ is a binary indica-
tor denoting individuals with an alcohol diagnosis who did not
receive treatment. The variable labeled ‘‘T*Alcohol Control’’ denotes
the interaction between postindex expenditures and an alcohol diag-
nosis without treatment. ‘‘Nonalcohol Control’’ is a binary indicator
denoting individuals without an alcohol diagnosis. The variable
labeled ‘‘T*Nonalcohol Control’’ denotes the interaction between
postindex expenditures and no alcohol diagnosis. X refers to all other
covariates. In addition to the demographic and clinical characteristics
included in Table 1, covariates included health plan type (indemnity,
preferred provider organization, health maintenance organization);
the primary insured’s employee type (salary or hourly) and status
(actively employed or retired); the median income in the 3-digit zip
code area corresponding to the patient’s residence; and binary indica-
tors for a pre-index substance abuse diagnosis, pre-index psychother-
apy, and postindex psychotherapy.
Ultimately, DID regression analyses, using the equation below,
provided an estimate of the total impact on expenditures of naltrex-
one treatment.
DID ¼ ðĈNaltrexonePost  ĈNaltrexone PreÞ  ðĈControl Post  ĈControl PreÞ
This DID design compared the difference in healthcare expen-
ditures between the 6-month pre-index period and the 6-month
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study period for the naltrexone group to the same difference in
the other patient groups. The DID analysis also allowed us to
control for differences in mean baseline expenditures that could
be attributed to the health conditions that we did not measure.
RESULTS
Univariate Analyses
There were 1,138 patients in the naltrexone group. Follow-
ing matching, there were 3,411 alcohol controls and 3,410
nonalcohol controls. Because appropriate matches could not
be found for a few naltrexone patients, both control groups
were just short of a complete 3:1 match.
The demographic characteristics of the three groups are
presented in Table 1. Sixty-two percent of the patients were
men and the mean age was 45 years. The sample was distrib-
uted across the four geographic regions as follows: 24%
resided in the northeast, 36% in the north central region,
26% in the south and 14% in the west. Sixty percent were
employees, 34% spouses of insured employees, and 6% were
children or other dependents, nearly all of whom were
18 years of age or older. Most (72%) had noncapitated insur-
ance coverage. Several different insurance plan types were
represented in the sample, the most common of which was
the preferred provider organization (PPO), with one-third of
patients having this plan type. Some patients had index dates
in each year from 2000 through 2004, but most of the sample
had index dates in 2001, 2002, or 2003. As would be expected
given the matching, the control groups did not differ signifi-
cantly from the naltrexone group on any demographic
variable.
As shown in Table 1, although all groups had low comor-
bidity scores during the pre-index period, the naltrexone
group had more comorbid medical conditions than either
control group, as evidenced by significantly higher CCI and
CDS scores. Comorbidity scores were also generally low in all
three samples during the postindex period. However, during
this time, the CCI score of the naltrexone group was signifi-
cantly lower than that of the alcohol controls, but signifi-
cantly higher than that of the nonalcohol controls. Similar
trends were evident for the CDS scores. More naltrexone
patients than controls had drug-related claims in both the
pre- and postindex periods (data not shown).
The corresponding expenditure results were similar, as
shown in Fig. 1. Mean pre-index alcohol-related expenditures
were significantly higher for the naltrexone group than the
alcohol controls ($1,352 vs. $68, p < 0.001). (Expenditures
related to naltrexone, disulfiram or acamprosate during this
period amounted to only $13 of total expenditures for the nal-
trexone group; data not shown.) Naltrexone patients also had
higher mean pre-index nonalcohol-related ($3,478 vs. $2,435,
p < 0.001) and total (alcohol-related plus nonalcohol-related)




(N = 3,411) p-valuea
Nonalcohol controls
(N = 3,410) p-valueb
Gender (%)
Male 61.6% 62% 0.9965 62% 0.9936
Female 38.4% 38% 0.9955 38% 0.9919
Mean age (SD) 44.9 (10.6) 44.6 (11.5) 0.4000 44.8 (11.0) 0.6804
Geographic region (%)
Northeast 24.3% 24.3% 0.9982 24.2% 0.9799
North Central 36.4% 36.4% 0.9941 36.4% 0.9921
South 26.8% 25.7% 0.9921 25.8% 0.9934
West 13.6% 13.6% 0.9964 13.6% 0.9952
Relationship to primary insured (%)
Self (Insured Employee) 60.2% 64.4% 0.4629 65.0% 0.4016
Spouse 33.7% 26.6% 0.0716 29.7% 0.3247
Child ⁄ other 6.2% 9.1% 0.1382 5.4% 0.6488
Insurance plan type (%)
Capitated 27.8% 30.7% 0.4463 28.7% 0.7991
Noncapitated 71.9% 69.2% 0.6551 71.1% 0.8919
Missing ⁄ unknown 0.4% 0.1% 0.4335 0.2% 0.6995
Index year (%)
2000 12.6% 12.7% 0.9965 12.7% 0.9954
2001 26.5% 26.4% 0.9987 26.4% 0.9813
2002 30.0% 30.0% 0.9946 30.0% 0.9929
2003 25.0% 25.0% 0.9951 25.0% 0.9935
2004 6.0% 5.9% 0.9757 6.0% 0.9968
Charlson comorbidity index (CCI) mean (SD)
Pre-index period 0.54 (1.01) 0.44 (1.10) 0.0026 0.21 (0.72) <0.0001
Postindex period 0.58 (1.20) 0.76 (1.47) <0.0001 0.23 (0.80) <0.0001
Chronic disease score (CDS) mean (SD)
Pre-index period 1.44 (1.89) 0.98 (1.72) <0.0001 0.58 (1.33) <0.0001
Postindex period 0.91 (1.67) 0.97 (1.74) 0.2582 0.51 (1.25) <0.0001
aComparison of naltrexone group and alcohol controls.
bComparison of naltrexone group and nonalcohol controls.
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expenditures than either the alcohol controls or the nonalco-
hol controls ($4,829 vs. $2,503, p < 0.001 and vs. $1,404,
p < 0.001, respectively). In the postindex period, mean
alcohol-related expenditures were higher in the naltrexone
group than in the alcohol controls ($1,415 vs. $882,
p < 0.001). (These expenditures included $268 for naltrex-
one, disulfiram, or acamprosate prescriptions; data not
shown.) Nonalcohol-related expenditures did not differ sig-
nificantly between these two groups ($4,005 vs. $3,694,
p = 0.16). Mean total expenditures for the naltrexone
group were higher than for both control groups ($5,420 vs.
$4,576 for alcohol controls and $1,496 for nonalcohol con-
trols, p < 0.001).
Comparing the difference between pre-index period and
postindex period expenditures, however, indicated that the
alcohol-related expenditures for the naltrexone group were
only $63 dollars higher in the postindex period than in the
pre-index period, while the difference for the controls with an
alcohol-related diagnosis was an increase of $814
(p < 0.0001). The smaller pre-post difference for the naltrex-
one group is especially notable given that these patients
incurred postindex expenditures for naltrexone prescriptions,
while the alcohol controls had no such expenditures in the
postindex period. The trends for nonalcohol-related and total
expenditures were similar to those for alcohol-related expen-
ditures.
Specific types of service utilization are shown in Table 2.
As can be seen there, a small proportion (<5%) of patients
Fig. 1. Mean alcohol and nonalcohol expenditures during the 6-month
pre-index and post-index periods.




(N = 3,411) p-valuea
Nonalcohol controls
(N = 3,410) p-valueb
Pre-index period N (%) with any utilization
Alcohol-related
Inpatient admission 241 (21.2) 29 (0.9) <0.0001 – –
Inpatient detoxification 142 (12.5) 17 (0.5) <0.0001 – –
ED visit 202 (17.8) 21 (0.6) <0.0001 – –
Outpatient office visit 570 (50.1) 179 (5.3) <0.0001 – –
Outpatient detoxification 11 (1.0) 1 (0.03) 0.0643 – –
Outpatient psychotherapy 189 (16.6) 103 (3.0) <0.0,001 – –
Oral naltrexonec 52 (4.6) – – – –
Disulfiram ⁄ acamprosatec 25 (2.2) – – – –
Nonalcohol-related
Inpatient admission 300 (26.4) 395 (11.6) <0.0001 92 (2.7) <0.0001
ED visit 420 (36.9) 821 (24.1) 0.0012 265 (7.8) <0.0001
Outpatient office visit 1,045 (91.8) 2,724 (79.9) 0.0719 2,311 (67.8) 0.0002
Outpatient prescriptions 1,039 (91.3) 2,593 (76.0) 0.0199 2,181 (64.0) <0.0001
Post-index period N (%) with any utilization
Alcohol-related
Inpatient admission 100 (8.8) 338 (9.9) 0.6092 – –
Inpatient detoxification 61 (5.4) 188 (5.5) 0.9280 – –
ED visit 98 (8.6) 497 (14.6) 0.0148 – –
Outpatient office visit 596 (52.4) 2,062 (60.5) 0.1340 – –
Outpatient detoxification 3 (0.3) 15 (0.4) 0.6790 – –
Outpatient psychotherapy 274 (24.1) 734 (21.5) 0.4553 – –
Oral naltrexone 1,138 (100) – – – –
Disulfiram or acamprosate 135 (11.9) – – – –
Nonalcohol-related
Inpatient admission 182 (16.0) 771 (22.6) 0.0360 75 (2.2) <0.0001
ED visit 319 (28.0) 1,257 (36.9) 0.0310 273 (8.0) <0.0001
Outpatient office visit 1,058 (93.0) 3,025 (88.7) 0.5308 2,345 (68.8) 0.0002
Outpatient prescriptions 1,091 (95.9) 2,820 (82.7) 0.0516 2,205 (64.7) <0.0001
aComparison of naltrexone group and alcohol controls.
bComparison of naltrexone group and nonalcohol controls.
cPatients in the naltrexone group had no naltrexone, disulfiram, or acamprosate claims in the 3 months pre-index, but may have used these
medications prior to that time.
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in the naltrexone group had claims for oral naltrexone or
disulfiram ⁄acamprosate in the pre-index period, but more
than 3 months prior to the index date. Given the requirement
that controls be free of these medications, no such use was
seen among the alcohol controls. One-half of the naltrexone
group had an alcohol-related physician office visit in the pre-
period, compared to only 5% of the alcohol controls
(p < 0.0001). The corresponding rates for outpatient alco-
hol-related psychotherapy visits were 17 and 3% (p <
0.0001). A larger proportion of the naltrexone group also uti-
lized nonalcohol-related services in the pre-index period than
either of the control groups, with nearly all comparisons being
highly statistically significant.
In the postindex period, however, only the rate of
alcohol-related ED visits differed significantly between
these groups, with the alcohol controls being more likely
to experience an alcohol-related ED visit [15% compared
to only 9% of naltrexone patients (p = 0.015)]. In the
postindex period, alcohol controls also were more likely
than naltrexone patients to have nonalcohol-related inpa-
tient admissions and ED visits (p = 0.036 and p = 0.031,
respectively). The percentage of patients with outpatient
physician visits or prescription drug use was higher in the
naltrexone group than the alcohol controls, although not
significantly so (p = 0.53 and p = 0.052, respectively). In
the postindex period, nonalcohol controls used significantly
fewer nonalcohol-related services than did naltrexone
patients (all categories of services showing highly significant
differences).
Multivariate Analyses
After adjusting for baseline differences, we observed that
the trend over time in expenditures was significantly higher
for alcohol controls than for the naltrexone group. The aver-
age medical care expenditures for the naltrexone group before
and after treatment relative to the alcohol controls with the
same characteristics were predicted from the model using sim-
ulations. The expenditure trend estimates are noted in
Table 3. They suggest that average alcohol-related, nonalco-
hol-related, and total expenditures for the naltrexone group
increased over time by about $58, $654, and $732, respec-
tively, per patient, while average expenditures for alcohol
controls increased by about $815, $1,590, and $2,559, respec-
tively. Thus, the use of naltrexone resulted in an overall
savings in total healthcare expenditures of about $1,827 per
patient (i.e., $732 ) $2,559 = )$1,827; p-value < 0.0001).
Results using alternate modeling strategies, such as ordinary
least squares regression, were similar, although the magnitude
of the savings estimate in total healthcare expenditures associ-
ated with naltrexone use was somewhat lower, ranging from
$1,442 to $1,483.
DISCUSSION
Univariate comparisons indicated that the three groups
were matched successfully on demographic measures.
Although overall the study groups had a low level of comor-
bidity, the descriptive results identified some differences
between the naltrexone and control groups on these measures,
which were controlled for in the multivariate analysis.
Naltrexone patients had higher mean total healthcare
expenditures than patients without an alcohol-related disor-
der, in part because of the expenditures for naltrexone
and alcohol-related services. A similar comparison showed
significantly higher mean nonalcohol-related expenditures,
consistent with prior findings that the healthcare impact of
alcohol-related disorders extends beyond alcohol-related
services (Parthasarathy et al., 2001).
Naltrexone use was associated with a reduction in both
alcohol-related and nonalcohol-related healthcare expendi-
tures among patients with alcohol-related diagnoses. The sav-
ings occurred over a relatively short timeframe – 6 months
after the initiation of naltrexone therapy – and were signifi-
cant despite the fact that naltrexone patients incurred costs
for naltrexone pharmacotherapy that the controls did not
incur.
Following an initial increase in costs, which is thought to
reflect a pent-up need for health care that is finally being met
in the course of early recovery (Holder and Blose, 1992), there
was a decrease in the use of more costly, intensive treatment
services, such as ED visits and inpatient stays, which trans-
lated overall into a smaller increase in costs than was seen
among the alcohol controls. The detection of a differential
economic benefit with naltrexone within only 6 months of its
initiation may reflect a benefit of adding the medication to
alcoholism treatment not only in terms of cost but also in
time.
Figure 1 shows that the greater increase in healthcare costs
over time in the alcohol controls were because of the lower
alcohol-related and nonalcohol-related costs in this group
than in the naltrexone group during the pre-period. During
the postperiod, alcohol-related and nonalcohol-related costs
were comparable in the two groups. We would speculate that
this reflects a stabilization of the naltrexone group’s course. In
contrast, in the absence of naltrexone, the alcohol controls
may have shown the cumulative adverse medical effects of
continued heavy drinking, which were reflected in both alco-
hol-related and alcohol-nonrelated costs. Correlation of the
change in healthcare costs with data on drinking behavior,
which were not available for use in this study, would make it
Table 3. Change in Expenditures Pre- and Postindex After Controlling for
Confounders in the Multivariate Analysis
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possible to evaluate this hypothesis and should be the focus of
subsequent studies.
The differences in healthcare utilization between the nal-
trexone group and the alcohol controls are also reflected in
the kinds of alcohol-related services that were utilized and
how these changed over time. In the preperiod, the naltrexone
group made significantly more alcohol-related outpatient
medical and psychotherapy visits and ED visits, consistent
with the adverse consequences of heavy drinking. Interven-
tions, which included the prescribing of naltrexone, appeared
to stabilize these individuals’ course. In contrast, utilization of
these services by the alcohol control group, which was low
during the preperiod, increased dramatically during the post-
period, consistent with cumulative adverse consequences of
heavy drinking and efforts by their healthcare practitioners to
treat their alcohol-related disorders.
In short, the naltrexone group and the alcohol controls,
despite being matched on a variety of demographic and clini-
cal variables during the preperiod, differed on a variety of
measures of healthcare utilization. It appears that the naltrex-
one group was prescribed this opioid antagonist medication
in the context of a variety of alcohol-related healthcare ser-
vices. Using utilization data, it is not possible to partial out
the impact of the naltrexone per se and an alternate explana-
tion for the observed trajectories is that factors other than nal-
trexone (i.e., both treatment-related and possibly reflecting
regression to the mean) were responsible for the differential
change in healthcare utilization between the naltrexone group
and the alcohol controls.
This study has a number of strengths, including the use of
two comparison groups, one of which was diagnosed with an
alcohol-related disorder and the other without such a diagno-
sis, which made it possible to evaluate temporal trends that
might otherwise confound the interpretation of the findings
(Holder and Blose, 1992). The use of GEE accounted for the
autocorrelation that occurs among individuals with repeated
measurements (Liang and Zeger, 1986). Finally, the detailed
healthcare utilization information available made it possible
to examine different modalities of treatment received, both
alcohol-related and nonalcohol-related, resulting in a more
detailed and revealing analysis of the impact of naltrexone
treatment on healthcare utilization.
These results should be interpreted in light of the usual limi-
tations of analyses using administrative data. Because this
study used only information available on insurance claims, it
was necessary to include patients with a variety of alcohol-
related disorders, which served as a proxy measure of an alco-
hol use disorder and it was not possible to stratify patients by
the level of severity of their alcohol-related disorder. Because
data for individuals with an oral naltrexone claim who did
not meet all study inclusion and exclusion criteria were not
extracted from the database, it was not possible to compare
the characteristics of excluded oral naltrexone patients to the
study sample. Psychiatric comorbidity may have differed by
cohort, but was not assessed. Nor was it possible to ascertain
patients’ motivation to seek alcohol-related services. There
was no way to verify that patients with an alcohol-related
diagnosis did, in fact, have such a diagnosis and some patients
in the control group without an alcohol-related diagnosis
could have had an alcohol-related disorder that was not
coded in their insurance claims. Naltrexone is also approved
to treat opioid dependence, so it is possible that some individ-
uals were prescribed naltrexone to treat that disorder, rather
than an alcohol-related disorder. Because naltrexone is pre-
scribed for opioid dependence infrequently, it is unlikely that
this is an important consideration in the interpretation of the
data presented here. Some patients in the naltrexone group
had evidence of pre-index use of naltrexone, disulfiram, or
acamprosate. Although the small number of such patients
suggests that their impact on study results was minimal, this
was not specifically assessed. In addition, because only ser-
vices billed to insurers could be quantified, we were unable to
assess modalities such as participation in Alcoholics Anony-
mous, so it is not known whether their utilization differed
between the naltrexone and control groups.
Despite these limitations, the findings of this analysis are
notable. They suggest that there is a cost savings to payers of
making treatment with naltrexone available to their enrollees.
The pre-to-post decrease in nonalcohol-related healthcare uti-
lization seen among the naltrexone patients but not among
the alcohol controls indicates that naltrexone treatment may
also decrease the overall burden on the healthcare system.
It may be feasible to derive more benefit from naltrexone
treatment than is evident from these results. Rates of adher-
ence to treatment with oral naltrexone have been shown to
be poor, with most patients unable to complete a clinical
course of treatment (Harris et al., 2004; Hermos et al., 2004;
Kranzler et al., 2008). A prior analysis of data from the nal-
trexone group included in this study showed that of patients
prescribed oral naltrexone, nearly 86% did not fill their pre-
scriptions for at least 80% of the days over a 6-month period
and approximately 50% failed to refill even one prescription
(Kranzler et al., 2008). Patients who persisted in refilling at
least 80% of the prescriptions during the 6-month period
showed significantly lower rates of use of intensive medical
services compared to patients who did not meet this persis-
tence criterion, including fewer ED contacts, hospital admis-
sions, and inpatient alcohol detoxifications. This finding has
relevance for the question of whether the different trajectories
of the naltrexone group and the alcohol controls were because
of treatment with the medication. Although it is possible that
naltrexone was prescribed to individuals who were perceived
to have a better prognosis, the low persistence rate for
naltrexone argues against this interpretation. Further, the
higher alcohol-related healthcare costs in the naltrexone
group than the alcohol controls during the pre-index period is
inconsistent with the notion that the naltrexone group was
more stable during this period than the alcohol controls.
These observations underscore the potential importance
of initiating medication treatment for alcohol dependence
and of optimizing medication adherence. Such efforts can
include behavioral approaches (e.g., daily observed pill
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administration) that have been shown to enhance adherence
(Cramer et al., 2003; O’Farrell et al., 1995; Pettinati et al.,
2000; Starosta et al., 2006) or long-acting preparations such
as extended-release injectable naltrexone (Garbutt et al.,
2005).
Finally, because of the relatively short duration of monitor-
ing, the observed effects on healthcare utilization may be an
underestimate of the actual impact. Additional studies using a
longer duration of monitoring appear warranted to estimate
more accurately the cost offset resulting from the use of nal-
trexone to treat alcoholism. Particular attention is also
required to differentiate the effects of the medication from
co-occurring interventions that follow from the recognition
by healthcare practitioners that an individual’s drinking is
problematic.
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